Myo-Inositol, graded Moderate-evidence on Magellan — the review behind the 2023 international PCOS guideline calls the overall evidence limited and inconclusive, with metformin better on several outcomes. No numeric effect size is reported for Myo-Inositol in Magellan's graded summary. Studied dose: 2–4 g/day.
Source: Reprod Biol Endocrinol 2023, PMID 36703143 ↗ · Nutraceuticals & Cellular Energizers · How Magellan grades evidence · Study write-up · evidence confidence: high
Myo-inositol is a naturally occurring sugar-like compound (a cyclitol, the most abundant of nine inositol stereoisomers) that the human body synthesizes and also obtains from foods such as fruits, beans, grains, and nuts. It is a structural component of cell membranes and a precursor of inositol-phosphoglycan second messengers that mediate insulin signal transduction, influencing glucose uptake and ovarian function. In insulin-resistant states such as polycystic ovary syndrome (PCOS), altered inositol metabolism is thought to contribute to impaired insulin signaling.
In randomized trials and meta-analyses, myo-inositol (often combined with D-chiro-inositol) has been associated with improved insulin sensitivity—lower fasting insulin and HOMA-IR—restoration of menstrual regularity and ovulation in PCOS, and a reduced incidence of gestational diabetes (a Cochrane review found roughly half the risk, with low certainty), with a favorable safety profile and fewer gastrointestinal effects than metformin. It has also improved metabolic-syndrome markers such as blood pressure, HOMA-IR and lipids in postmenopausal women. Evidence quality is mixed, however: the systematic review informing the 2023 international PCOS guidelines judged the overall evidence 'limited and inconclusive' and found metformin superior on several outcomes, most trials are short, many gestational-diabetes trials are small and from a single country, and aging or longevity outcomes are essentially unstudied. This evidence describes the compound myo-inositol and its mechanism, not this specific commercial product.
Peer-reviewed studies on the active compound — citations link to PubMed.
“Inositol is an effective and safe treatment in PCOS”
“myoinositol acts as an insulin sensitizer and exerts beneficial effects in PCOS”
“The insulin sensitivity improved in both treatment groups”
“Evidence suggests benefits for myo-inositol or D-chiro-inositol (DCI) for some metabolic measures and potential benefits from DCI for ovulation, but inositol may have no effect on other outcomes.”
“Myo-inositol and d-chiro-inositol in combination (3.6:1 ratio) are effective in regularizing menstrual cycles and improving insulin resistance.”
“Myo had improvement in fasting insulin, HOMA, Sr.AMH, and SHBG suggesting decreased insulin resistance.”
Research describes the active mechanism and is not a claim about this specific product.
Across large randomized trials and meta-analyses, marine omega-3s reliably reduce serum…
Across meta-analyses and randomized trials, creatine monohydrate combined with…
In humans, randomized trials and meta-analyses most consistently show that astaxanthin…
Multiple meta-analyses of randomized trials indicate that oral zinc, started soon after…
Yes — its active compound is linked to 17 peer-reviewed studies, summarized and cited above.
You can buy it on Amazon via the link above; Magellan earns a small affiliate commission at no extra cost to you, which does not affect the evidence grade.
Dietary supplements and devices are generally well tolerated but are not a substitute for medical care. Talk to your physician before starting, especially if you take medication or have a health condition.